- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01766037
Pivotal Aspiration Therapy With Adjusted Lifestyle Therapy Study (PATHWAY)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The Aspiration process works by "correcting" meal portions after eating by removing some of the food left in your stomach 20 minutes after your meal, which reduces the number of calories absorbed by your body. This is done through a tube placed through the abdomen into the stomach with a small valve attached at the surface of your skin. An aspiration system will attach to that valve after each major meal of the day and allow you to remove a portion of that meal.
During this study you will also be provided with Lifestyle therapy which includes behavioral therapy, diet and physical activity education. This Lifestyle therapy will also be provided to the participants who do not receive the AspireAssist so that the two groups can be compared and the benefit of aspiration for weight loss can be determined.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
San Diego, California, United States, 92161
- Dept VA San Diego Health Care System
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20060
- Howard University Center for Wellness and Weight Loss Surgery
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Brigham and Women's Hospital
-
Boston, Massachusetts, United States, 02118
- Boston Medical Center
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
New York
-
New York, New York, United States, 10065
- Weill Cornell Medical College
-
-
Pennsylvania
-
Langhorne, Pennsylvania, United States, 19047
- St. Mary Medical Center
-
Philadelphia, Pennsylvania, United States, 19146
- University of Pennsylvania Center for Weight and Eating Disorders
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Measured BMI of 35.0-55.0 kg/m2 at time of screening.
- 21- 65 years of age (inclusive) at time of screening.
- Failed attempt for a duration equal to 3-months at weight loss by alternative approaches (e.g. supervised or unsupervised diets, exercise, behavioral modification programs).
- Stable weight (<3% change in self-reported weight) over the previous 3 months at time of screening).
- Women of childbearing potential must agree to use at least one form of birth control (prescription hormonal contraceptives, diaphragm, IUD, condoms with or without spermicide, or voluntary abstinence) from time of study enrollment through study exit.
- Willing and able to provide informed consent in English and comply with the protocol.
Exclusion Criteria:
- Previous abdominal surgery that significantly increases the medical risks of gastrostomy tube placement
- Esophageal stricture, pseudo-obstruction, severe gastroparesis or gastric outlet obstruction, inflammatory bowel disease
- History of refractory gastric ulcers
- Ulcers, bleeding lesions, or tumors discovered during endoscopic examination.
- History of radiation therapy to the chest or abdomen
- Uncontrolled hypertension (blood pressure >160/100).
- Diabetes treated with insulin or sulfonylurea medications
- Any change in diabetes medication in previous 3 months
- Hemoglobin A1C >9.5%
History or evidence of serious pulmonary or cardiovascular disease, including acute coronary syndrome, heart failure requiring medications, or NYHA (New York Heart Association) class III or IV heart failure (defined below):
Class III: patients with marked limitation of activity and who are comfortable only at rest Class IV: patients who should be at complete rest, confined to bed or chair and who have discomfort with any physical activity
- Coagulation disorders (platelets < 100,000, PT > 2 seconds above control or INR > 1.5)
- Anemia (Hemoglobin <11.0 g/dL in women and <12.5 g/dL in men)
- Liver enzymes (ALT and AST) ≥3.0 times the upper limit of normal
- Thyroid Stimulating Hormone (TSH) >1.5 x upper limit of normal at screening.
- Osteoporosis (DEXA T-Score ≤ -2.5 standard deviations below normal peak values).
- History of fragility fractures (fractures resulting from a fall from a standing height or less, or presenting in the absence of obvious trauma)
- Pregnant or lactating
- Diagnosed Bulimia or diagnosed Binge Eating Disorder (using DSM IV criteria)
- Night Eating Syndrome (diagnosed by EDE)
- Serum potassium < 3.8 mEq/L
- Chronic abdominal pain that would potentially complicate the management of the device
- Taking a GLP-1 agonist < 6 months.
- Taking prescription or over-the-counter medications for weight loss in the last 3 months before screening, or planning to participate in a commercial weight loss program in the next 24 months.
- Taking medication once or more per week that causes weight gain (e.g. atypical antipsychotics, monoamine oxidase inhibitors, lithium, selected anticonvulsants, tamoxifen, glucocorticoids)
- Self- reported history of substance abuse in last 3 years.
- Malignancy in the last 5 years (except for non-melanoma skin cancer).
- Physical or mental disability, or psychological illness that could interfere with compliance with the therapy.
- At high risk of having a medical complication from the endoscopic procedure or Aspiration Therapy weight loss program for any reason, including poor general health or severe organ dysfunction, such as cirrhosis or renal dysfunction (GFR <60 mL/min/1.73 m2 at screening, calculated by using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Aspiration Therapy
Aspiration Therapy and Lifestyle Therapy
|
Use of the AspireAssist device in aspiration therapy
Other Names:
Lifestyle therapy is a behavioral, diet and physical activity education program
Other Names:
|
ACTIVE_COMPARATOR: Lifestyle Therapy
Lifestyle Therapy only
|
Lifestyle therapy is a behavioral, diet and physical activity education program
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Percent Excess Weight Loss (%EWL)
Time Frame: 52 weeks
|
The first effectiveness co-primary endpoint is the mean percent excess weight loss (%EWL) at 52-weeks.
The hypothesis for the first primary effectiveness endpoint is that the difference in the mean percent excess weight loss (%EWL) at 52-weeks for the Aspiration Therapy (AT) group and Control group is at least 10%.
Percent EWL is defined as absolute weight loss divided by baseline excess weight and multiplied by 100.
Excess weight is determined from ideal body weights based on a BMI=25 kg/m2.
|
52 weeks
|
% of Subjects Who Achieve >25% EWL
Time Frame: 52 weeks
|
The second co-primary effectiveness endpoint is that at least 50% of the AT group at 52-weeks achieve > 25% EWL.
|
52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Percent Total Body Weight Loss
Time Frame: 52 weeks
|
i) Mean percent absolute weight loss in AT compared to Control group
|
52 weeks
|
Percent of Subjects With ≥10% Total Body Weight Loss
Time Frame: 52 weeks
|
ii) proportion of subjects who achieve ≥10% absolute weight loss in AT compared to Control group
|
52 weeks
|
Mean Percent Change in Serum Lipids
Time Frame: 52 weeks
|
iii) mean percent change serum lipids (triglyceride, HDL-cholesterol and LDL-cholesterol concentration) in the AT group compared to the control group
|
52 weeks
|
Mean Percent Change in Blood Pressure
Time Frame: 52 weeks
|
iv) mean percent change in systolic and diastolic blood pressures in the AT group compared to the control group
|
52 weeks
|
Mean Change in Score for IWQOL Questionnaire
Time Frame: 52 weeks
|
v) "Impact of Weight on Quality of Life" (IWQOL) questionnaire total score Total score ranges from a minimum of 0 to a maximum of 100. Based on the algorithm developed by Crosby, et.al., patients' IWQOLLite total scores are considered to have shown meaningful improvement from baseline to one year if they increased between 7 and 12 points, depending upon baseline severity in comparison to the normative mean. Normative means for the IWQOL-Lite have been derived from a sample of 534 non-obese individuals who were not enrolled in any weight loss treatment program [238 women and 296 men with BMI's between 18.5 and 29.9]. The data presented is the mean change in total score. The AT group demonstrated a mean improvement (increase) in score of 16.3 points, the Control group a mean improvement (increase) of 11.7 points. |
52 weeks
|
Mean Change in Hemoglobin A1C
Time Frame: 52 weeks
|
vi) change in mean hemoglobin A1C (only subjects with T2 diabetes at baseline).
Hemoglobin A1C is measured as DCCT%.
The change in mean DCCT% from Baseline to Week 52 is reported for this secondary endpoint.
|
52 weeks
|
Procedural Success
Time Frame: 52 weeks
|
vii) percent procedural success (defined as successful endoscopic placement of the A-Tube) in all subjects undergoing endoscopy
|
52 weeks
|
Change in Medication for Hypertension
Time Frame: 52 weeks
|
Percent change in the number of medications taken by subjects for hypertension
|
52 weeks
|
Change in Medications for Dyslipidemia
Time Frame: 52 weeks
|
Percent change in the number of medications taken by subjects for dyslipidemia
|
52 weeks
|
Change in Medications for Type 2 Diabetes
Time Frame: 52 weeks
|
Percent change in the number of medications taken by subjects for Type 2 Diabetes
|
52 weeks
|
Change in Number of Subjects on Hypertension Medication
Time Frame: 52 weeks
|
Percent change in the number of subjects on Hypertension medication
|
52 weeks
|
Change in Number of Subjects on Dyslipidemia Medications
Time Frame: 52 weeks
|
Percent change in the number of subjects on Dyslipidemia medications
|
52 weeks
|
Change in Number of Subjects on Diabetes Medication
Time Frame: 52 weeks
|
Percent change in the number of subjects on Diabetes medication
|
52 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety Outcomes
Time Frame: 52 weeks
|
The incidence of procedure-related, device-related, and therapy-related serious adverse events.
Also, the development of adverse eating behaviors will be assessed.
|
52 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Christopher Thompson, MS, MD, Brigham and Women's Hospital
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- P12-001V
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Istituto Auxologico ItalianoRecruiting
Clinical Trials on Aspiration Therapy (AspireAssist)
-
The University of Hong KongAspire Bariatrics, Inc.Unknown
-
Blekinge County Council HospitalUnknown
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)CompletedPain | Hematopoietic/Lymphoid CancerUnited States
-
Huazhong University of Science and TechnologyUnknownHypertensive Intracerebral HemorrhageChina
-
The Netherlands Cancer InstituteCompletedBreast CancerNetherlands
-
RapidPulse, IncCompleted
-
Cedars-Sinai Medical CenterRecruiting
-
The Young Investigator Group of Cardiovascular...SuspendedCoronary Artery Disease | ST Elevation Myocardial Infarction | Percutaneous Coronary InterventionEgypt
-
University Medical Centre LjubljanaBlood Transfusion Centre of SloveniaRecruitingOsteoarthritis, KneeSlovenia
-
RapidPulse, IncNot yet recruiting